MedTrace Logo

A Multi-Strain Probiotic Reduces the Frequency of Diarrhea in IBS-D Patients

NCT05900752 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2023-11-24

No results posted yet for this study

Summary

The goal of this interventional clinical study is to study whether the consumption of QiMeiYan Probiotics in 25-35 young people with Mild irritable bowel syndrome (IBS Score 75 - 175) will reduce the frequency of Diarrhea.

140 eligible participants (70 males and 70 females) will be enrolled in two study sites and randomly assigned to two groups of products QiMeiYan Probiotics and placebo. All participants will consume assigned products once a day after meals and record the critical data such as photo of feces. Three site visits will be arranged and all clinical data will be captured and recorded into CTMS (Clinical Trial Management System) for statistical analysis.

Researchers will compare the two groups to validate if the daily consumption of QiMeiYan Probiotics will reduce the frequency of Diarrhea in the study population.

Conditions

  • IBS - Irritable Bowel Syndrome
  • Diarrhea

Interventions

DIETARY_SUPPLEMENT

QiMeiYan Probiotics

consume one sachet of the assigned product, once a day after meals.

DIETARY_SUPPLEMENT

Placebo product

consume one sachet of the assigned product, once a day after meals.

Sponsors & Collaborators

  • Shenzhen Precision Health Food Technology Co. Ltd.,

    lead OTHER_GOV

Principal Investigators

  • Ruiming Xu, MD · Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-19
Primary Completion
2023-07-16
Completion
2023-07-16

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05900752 on ClinicalTrials.gov